@article{0d01806f30e8421e92f94644e386ef81,
title = "Baseline characterization of the ARMADA (Assessing Reliable Measurement in Alzheimer's Disease) study cohorts",
abstract = "Introduction: The National Institutes of Health (NIH) Toolbox (NIHTB) provides computerized measures of cognition, emotion, sensation, and motor abilities across the lifespan. The ARMADA (Assessing Reliable Measurement in Alzheimer's Disease and Cognitive Aging) study validated the NIHTB in individuals across the cognitive aging spectrum. This article reports the characteristics of our sample of participants. Methods: Participants were recruited across nine sites and classified clinically as cognitively normal (NC), with mild cognitive impairment (MCI), or with dementia of the Alzheimer's type (DAT.) They completed the NIHTB at multiple time points and many had at least one Alzheimer's biomarker previously obtained. Results: Groups differed with respect to dementia severity levels, as anticipated, but were well-matched across many demographic characteristics. Discussion: The ARMADA study demographics and baseline characteristics provide a suitable sample for validating the NIHTB across the cognitive aging spectrum. Other enriched samples (African American participants, Spanish NIHTB, 85+ years of age) will be reported elsewhere. Highlights: There is a need for assessments that can detect the early stages of cognitive decline in older adults. The ARMADA (Assessing Reliable Measurement in Alzheimer's Disease and Cognitive Aging) study will validate the National Institutes of Health (NIH) Toolbox across the aging spectrum, including mild cognitive impairment (MCI) and dementia of the Alzheimer's type (DAT). Here we report the characteristics of participants. Groups were well-matched across most demographic characteristics, and clinical characteristics differed as expected. ARMADA study cohorts reflect their respective clinical syndromes for validating the NIH Toolbox.",
keywords = "aging, Alzheimer's disease, cognition, dementia, mild cognitive impairment, NIH Toolbox",
author = "Tatiana Karpouzian-Rogers and Ho, {Emily H} and Miriam Novack and Miriam Chinkers and Katy Bedjeti and Cindy Nowinski and Bruno Giordani and Richard Gershon and Sandra Weintraub",
note = "Funding Information: The authors would like to thank the study participants and their family members for their time and participation in this study. We also thank the research staff across all sites for their help in carrying out this study. (1) Mayo Clinic Florida: National Institute on Aging (NIA) P50 AG016574 Mayo Clinic Alzheimer's Disease Research Center; Florida Department of Health Ed & Ethel Moore Alzheimer's Disease Research Program grant 8AZ08 Evaluating The Impact of a Dementia‐Caring Community Model on African Americans with Alzheimer's Disease and Their Care Partners; (2) Emory University: NIA 1P30AG066511 Goizueta Alzheimer's Disease Research Center at Emory University; (3) University of California, San Diego: NIA P30AG062429 UCSD Alzheimer's Disease Research Center; (4) NACC NIA U01 AG16976, National Alzheimer's Coordinating Center; (5) Northwestern University: NIA P30 AG013854, Northwestern Alzheimer's Disease Center; NIA R01AG045571, R56AG045571, and R01AG067781, Cognitive SuperAging studies; (6) University of Pittsburgh: NIA P50 AG005133, Alzheimer's Disease Research Center, NIA P01 AG025204, Imaging Pathophysiology in Aging and Neurodegeneration, NIA R01 AG052446, Role of Midlife Cardiovascular Disease on Alzheimer's Pathology and Cerebrovascular Reactivity in the Young‐Old; (7) Massachusetts General Hospital: NIA P30AG062421, Massachusetts ADRC, NCBI P01AG036694 Harvard Aging Brain Study; (8) University of Michigan: NIA P30 AG053760, Michigan Alzheimer's Disease Research Center; NIA R01 AG054484, Community Based Approach to Early Detection of Transitions to Mild Cognitive Impairment and Alzheimer's Disease in African Americans (ELECTRA); NIA R01 AG058724, Treating Mild Cognitive Impairment with High Definition Transcranial Direct Current Stimulation (STIM); NIH RF1 AG047866, Impact of Disclosing Amyloid Imaging Results to Cognitively Normal Individuals (REVEAL SCAN); Cure Alzheimer's Fund, Deep Phenotyping of Older African Americans at Risk of Dementia; (9) Columbia University: Washington Heights‐Inwood Columbia Aging Project (WHICAP), NIA PO1AG07232, R01AG037212, RF1AG054023, National Center for Advancing Translational Sciences, National Institutes of Health, through Grant Number UL1TR001873; (10) University of Wisconsin: NIA P50 AG033514 and NIA P30 AG062715 Wisconsin Alzheimer's Disease Research Center; and (11) Oregon Health & Science University: Layton Aging and Alzheimer's Disease Center, NIA P30 AG066518. Publisher Copyright: {\textcopyright} 2022 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.",
year = "2022",
doi = "10.1002/alz.12816",
language = "English (US)",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
}
